The presence of a FLT3 mutation in AML adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the MRC AML 10 and 12 trials

Kottaridis, P. D., Gale, R. E., Frew, M. E., Harrison, G., Langabeer, S. E., Belton, A. A., Walker, H., Wheatley, K., Bowen, D. T., Burnett, Alan Kenneth, Goldstone, A. H. and Linch, D. C. 2000. The presence of a FLT3 mutation in AML adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the MRC AML 10 and 12 trials. Blood 96 (11) , 825A-825A.

Full text not available from this repository.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > R Medicine (General)
Publisher:	American Society of Hematology
ISSN:	0006-4971
Last Modified:	25 Jun 2017 04:50
URI:	https://orca.cardiff.ac.uk/id/eprint/62440

Actions (repository staff only)

Edit Item

CORE (COnnecting REpositories)

CORE (COnnecting REpositories)

CORE (COnnecting REpositories)